Last updated: 2026-09-09 10:30:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Xeris Biopharma Holdings, Inc. (XERS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8,48, with a market capitalization of $1,56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,25 to $10,08. This page covers its latest market performance, valuation, price trends and company information.
$1,56B | |
$8,39 | |
$27,98 | |
$0,97 | |
$8,53 | |
972,88K | |
1,86M | |
-- | |
$10,08 | |
$5,25 | |
-- | |
-- |
Xeris Biopharma Holdings, Inc. (XERS) is trading at $8,57 in pre-market trading as of 2026-09-08 23:31:00, up 0,47% ($0,04) from the previous close of $8,53
Pre-market trading shows how investors are pricing XERS before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Xeris Biopharma Holdings, Inc. (XERS) moved from $8,48 to $8,48, representing a decline of 0,06% ($0,01).
The stock traded between $8,22 and $8,78 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1,27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66,8%
XERS is currently trading at $8,48, placing it 66,8% of the way from its 52-week low of $5,25 to its 52-week high of $10,08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 435 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xeris Biopharma Holdings, Inc. (XERS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.